Market closedNon-fractional
Iovance Biotherapeutics/IOVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
IOVA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Carlos, United States
Employees
557
Website
www.iovance.com
IOVA Metrics
BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$1.81
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$2.6B
Beta
0.65
Financial strength
Current ratio
4.633
Quick ratio
4.283
Long term debt to equity
10.778
Total debt to equity
12.407
Management effectiveness
Return on assets (TTM)
-34.48%
Return on equity (TTM)
-66.77%
Valuation
Price to revenue (TTM)
1,229.626
Price to book
3.88
Price to tangible book (TTM)
6.84
Price to free cash flow (TTM)
-5.779
Growth
Earnings per share change (TTM)
-23.77%
3-year earnings per share growth (CAGR)
-0.67%
What the Analysts think about IOVA
Analyst Ratings
Majority rating from 14 analysts.
IOVA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$700K
75.00%
Net income
-$113M
-2.92%
Profit margin
-16,128.57%
-44.53%
IOVA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.46
-$0.45
-$0.42
-
Expected
-$0.80
-$0.45
-$0.43
-$0.42
-$0.34
Surprise
-40.99%
1.25%
4.28%
-0.59%
-
IOVA News
AllArticlesVideos
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
GlobeNewsWire·4 weeks ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $2.6B as of July 26, 2024.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of July 26, 2024.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Iovance Biotherapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.